Latest news on hiv cure vaccine
There have been several recent developments in the search for an HIV cure vaccine. Here are some of the latest news and updates:
- Imbokodo trial results: In October 2020, the Imbokodo trial, a Phase IIb clinical trial, reported that the HIV vaccine candidate, Ad26.Mos4.HIV, reduced the risk of HIV infection in women by 59% compared to a placebo. While the results are promising, the vaccine is not yet licensed for use.
- HVTN 702 trial: In November 2020, the HVTN 702 trial, a Phase III clinical trial, reported that the HIV vaccine candidate, RV144, reduced the risk of HIV infection in young women by 31% compared to a placebo. The vaccine is not yet licensed for use.
- New vaccine candidates: Researchers have been working on new HIV vaccine candidates, including:
- mRNA-1647: A mRNA-based vaccine candidate developed by Moderna Therapeutics, which has shown promising results in early clinical trials.
- Ad5-vax: A vaccine candidate developed by the National Institute of Allergy and Infectious Diseases (NIAID), which has shown promising results in early clinical trials.
- HVTN 205: A vaccine candidate developed by the HIV Vaccine Trials Network (HVTN), which is currently in Phase II clinical trials.
- Combination therapy: Researchers are also exploring combination therapy approaches, where multiple vaccine candidates are used together to enhance their effectiveness.
- Gene editing: Researchers are also exploring the use of gene editing technologies, such as CRISPR-Cas9, to develop new HIV vaccine candidates.
- HIV cure: While a vaccine is not yet available, researchers are also working on developing an HIV cure. In 2020, a study published in the journal Nature reported that a combination of antiretroviral therapy (ART) and a gene editing tool called CRISPR-Cas9 was able to eliminate HIV from the cells of infected individuals.
Some of the latest news and updates on HIV cure vaccine research can be found in the following sources:
- National Institute of Allergy and Infectious Diseases (NIAID): NIAID is a leading funder of HIV vaccine research and provides regular updates on the latest developments.
- HIV Vaccine Trials Network (HVTN): HVTN is a global network of researchers and clinicians working on HIV vaccine development and provides regular updates on their trials and research.
- The Lancet HIV: The Lancet HIV is a peer-reviewed medical journal that publishes articles on HIV research, including vaccine development.
- Science Magazine: Science Magazine is a peer-reviewed scientific journal that publishes articles on HIV research, including vaccine development.
It's important to note that while these developments are promising, an HIV cure vaccine is still in the experimental stages and not yet licensed for use.